MatthewKyleLabriolaMD

Matthew Labriola, M.D./Duke University Internal Medicine Resident

Dr. Labriola is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Duke University HospitalFellowship, Hematology and Medical Oncology, 2019 - 2022
Duke University HospitalResidency, Internal Medicine, 2016 - 2020
Duke University HospitalResidency, Internal Medicine, 2017 - 2019
Georgetown University School of MedicineClass of 2016

PubMed

1 citations
Patient engagement in designing and publishing research in prostate cancer: a scoping review.
Linda Sutton, Matthew Labriola, Thomas Bognanno, Shelby Moneer, Jennifer Ghith
Future Oncology. 2024-01-01
20 citations
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
Vadim S. Koshkin, Vaibhav G. Patel, Alicia Ali, Mehmet Asim Bilen, Deepak Ravindranathan
Prostate Cancer and Prostatic Diseases. 2021-08-06
62 citations
Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
Matthew Labriola, Jason Zhu, Rajan T. Gupta, Shannon J. McCall, Jennifer Jackson
Journal for Immunotherapy of Cancer. 2020-03-01

Lectures

Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic re...
2019 ASCO Annual Meeting - 6/1/2019
Concordance between PD-L1 assays for metastatic renal cell carcinoma (mRCC) and metastatic urothelial carcinoma (mUC).
2019 ASCO Annual Meeting - 6/1/2019